Skip to main content
. Author manuscript; available in PMC: 2010 Oct 5.
Published in final edited form as: Curr Opin Pharmacol. 2007 Oct 17;8(1):2–7. doi: 10.1016/j.coph.2007.09.002

Table 1.

Possible adenosine-based therapeutic strategies for neurological diseases

Condition A1R agonists A2AR antagonists ADK inhibitors adenosine delivery
Epilepsy X [1] ? [1] X [16] cell therapy [4]
Stroke X [1] X [1] ? [16] cell therapy [32]
Chronic pain X* [2] X [37] X* [34] intrathecal adenosine* [34]
Parkinson’s X* [38]
Alzheimer’s X [42]
Huntington’s ? [45]
Schizophrenia ? [46] ? [46] ? [46]

“X” indicates successful experimental studies, those marked with an asterisk* have been studied in clinical trials. “?” indicates therapeutic potential based on theoretical considerations and/or preliminary data, but experimental evidence needs to be established. References, with a focus on recent review articles, are given in brackets.